Novartis Takes option on Radius’ Osteoporosis Drug

By Business Review Editor

Pharma Deals Review: Vol 2007 Issue 88 (Table of Contents)

Published: 7 Oct-2007

DOI: 10.3833/pdr.v2007.i88.280     ISSN: 1756-7874

Section: Licensing



Radius Health granted Novartis an option to obtain an exclusive worldwide license to develop and commercialize all formulations of BA058 for treating postmenopausal osteoporosis...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details